Yvonne Y. Chen

Yvonne Y. Chen

Auto-generated profile, based on publicly available information

Yvonne Y. Chen

Molecular Biology Institute, University of California, Los Angeles, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Cancer Cell
Verified
Journal Article
Closed access
MHMihe Hong
Mihe Hong
JCJustin D. Clubb
Justin D. Clubb
YCYvonne Y. Chen
Yvonne Y. Chen

10 May 2021 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
AHAndrew J. Hou
Andrew J. Hou
LCLaurence C. Chen
Laurence C. Chen
YCYvonne Y. Chen
Yvonne Y. Chen

31 May 2016 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
EZEugenia Zah
Eugenia Zah
MLMeng-Yin Lin
Meng-Yin Lin
ASAnne Silva-Benedict
Anne Silva-Benedict
MJMichael C. Jensen
Michael C. Jensen
YCYvonne Y. Chen
Yvonne Y. Chen
The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs) has shown remarkable curative potential against advanced B-cell malignancies, but multiple trials have also reported patient relapses due to the emergence of CD19-negative leukemic cells. Here, we report the design and optimization of single-chain, bispecific CARs that trigger robust cytotoxicity against target cells expressing either CD19 or CD20, two clinically validated targets for B-cell malignancies. We determined the structural parameters required for efficient dual-antigen recognition, and we demonstrate that optimized bispecific CARs can control both wild-type B-cell lymphoma and CD19– mutants with equal efficiency in vivo. To our knowledge, this is the first bispecific CAR capable of preventing antigen escape by performing true OR-gate signal computation on a clinically relevant pair of tumor-associated antigens. The CD19-OR-CD20 CAR is fully compatible with existing T-cell manufacturing procedures and implementable by current clinical protocols. These results present an effective solution to the challenge of antigen escape in CD19 CAR T-cell therapy, and they highlight the utility of structure-based rational design in the development of receptors with higher-level complexity. Cancer Immunol Res; 4(6); 498–508. ©2016 AACR.See related Spotlight by Sadelain, p. 473.An addendum has been published.

16 January 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MCMelanie Ayala Ceja
Melanie Ayala Ceja
MKMobina Khericha
Mobina Khericha
CHCaitlin M. Harris
Caitlin M. Harris
CPCristina Puig-Saus
Cristina Puig-Saus
YCYvonne Y. Chen
Yvonne Y. Chen
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.

29 January 2018 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
ZCZeNan L Chang
ZeNan L Chang
MLMichael H Lorenzini
Michael H Lorenzini
XCXimin Chen
Ximin Chen
UTUyen Tran
Uyen Tran
NBNathanael J Bangayan
Nathanael J Bangayan
YCYvonne Y Chen
Yvonne Y Chen
Chimeric antigen receptor (CAR)-expressing T cells were engineered to recognize soluble protein ligands that, by inducing CAR dimerization, mechanically couple ligand binding and receptor signaling to produce immune effector molecules. Chimeric antigen receptor (CAR)-expressing T cells targeting surface-bound tumor antigens have yielded promising clinical outcomes, with two CD19 CAR-T cell therapies recently receiving FDA approval for the treatment of B-cell malignancies. The adoption of CARs for the recognition of soluble ligands, a distinct class of biomarkers in physiology and disease, could considerably broaden the utility of CARs in disease treatment. In this study, we demonstrate that CAR-T cells can be engineered to respond robustly to diverse soluble ligands, including the CD19 ectodomain, GFP variants, and transforming growth factor beta (TGF-β). We additionally show that CAR signaling in response to soluble ligands relies on ligand-mediated CAR dimerization and that CAR responsiveness to soluble ligands can be fine-tuned by adjusting the mechanical coupling between the CAR's ligand-binding and signaling domains. Our results support a role for mechanotransduction in CAR signaling and demonstrate an approach for systematically engineering immune-cell responses to soluble, extracellular ligands.

8 May 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
EZEugenia Zah
Eugenia Zah
ENEunwoo Nam
Eunwoo Nam
VBVinya Bhuvan
Vinya Bhuvan
UTUyen Tran
Uyen Tran
BJBrenda Y. Ji
Brenda Y. Ji
YCYvonne Y. Chen
Yvonne Y. Chen
Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse exists. Here we report the rational design and optimization of bispecific CAR-T cells with robust activity against heterogeneous multiple myeloma (MM) that is resistant to conventional CAR-T cell therapy targeting B-cell maturation antigen (BCMA). We demonstrate that BCMA/CS1 bispecific CAR-T cells exhibit superior CAR expression and function compared to T cells that co-express individual BCMA and CS1 CARs. Combination therapy with anti–PD-1 antibody further accelerates the rate of initial tumor clearance in vivo, while CAR-T cell treatment alone achieves durable tumor-free survival even upon tumor re-challenge. Taken together, the BCMA/CS1 bispecific CAR presents a promising treatment approach to prevent antigen escape in CAR-T cell therapy against MM, and the vertically integrated optimization process can be used to develop robust cell-based therapy against novel disease targets.